EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial

Evan S Dellon iD, Marc E Rothenberg, Jonathan M Spergel iD, Albert J Bredenoord, Antonella Cianferoni, Changming Xia iD, Margee Louisias, Allen Radin iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.71001 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Evan S Dellon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi and Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with eosinophilic oesophagitis (EoE) can present with differing disease characteristics, treatment resistance, and associated type 2 inflammatory comorbidities. We assessed the efficacy of dupilumab in subgroups of patients with EoE from the LIBERTY EoE TREET study across a range of demographics, characteristics, treatments, and comorbidities.

Methods

Patients were categorised by subgroups based on weight (< 60 kg or ≥ 60 kg), body mass index (< 18.5 kg/m 2 , ≥ 18.5 to < 30 kg/m 2 , ≥ 30 kg/m 2 ), disease duration before study entry (< 5 years, ≥ 5 to < 10 years, ≥ 10 years), history of type 2 inflammatory comorbidities (with/without asthma, allergic rhinitis, atopic dermatitis, or food allergy), history of elimination diet, concurrent elimination diet, concurrent proton pump inhibitor use, and prior oesophageal dilation. Outcomes were analysed post hoc and included the proportion of patients achieving ≤ 6 eosinophils per high‐power field (eos/hpf) and change from baseline in Dysphagia Symptom Questionnaire (DSQ) and total Endoscopic Reference Score (EREFS).

Results

At Week 24, dupilumab treatment increased the proportion of patients achieving histological remission (peak eosinophil count ≤ 6 eos/hpf) versus placebo in all subgroups. At Week 52, improvements were maintained with continued dupilumab treatment. Improvements were also observed through Week 52 in patients who switched from placebo to dupilumab at Week 24. Similar results were observed for change from baseline in DSQ and EREFS.

Conclusions

Dupilumab treatment improved histological, symptomatic, and endoscopic outcomes versus placebo in patients with EoE, regardless of demographics, disease characteristics, treatment history, or type 2 inflammatory disease comorbidities. Trial Registration ClinicalTrials.gov identifier: NCT03633617

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisAntibodies, Monoclonal, HumanizedHumansFemaleMaleTreatment OutcomeMiddle AgedAdultDouble-Blind MethodComorbidityElimination Diets

Stichwörter der Autor:innen

dupilumabeosinophilic oesophagitissubgroups

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Allergy and Immunology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
  • Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

ORCID-Profile: Evan S Dellon, Jonathan M Spergel, Changming Xia, Allen Radin

Förderung

  • Sanofi and Regeneron Pharmaceuticals Inc

Zitieren

APA

Dellon, E. S., Rothenberg, M. E., Spergel, J. M., Bredenoord, A. J., Cianferoni, A., Xia, C., Louisias, M., & Radin, A. (2026). Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71001

Vancouver

Dellon ES, Rothenberg ME, Spergel JM, Bredenoord AJ, Cianferoni A, Xia C, et al. Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71001

BibTeX
@article{Dellon2026,
  author = {Dellon, Evan S and Rothenberg, Marc E and Spergel, Jonathan M and Bredenoord, Albert J and Cianferoni, Antonella and Xia, Changming and Louisias, Margee and Radin, Allen},
  title = {Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.71001}
}
Kostenlos starten →